Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
January 5, 2006
Does IP chemotherapy improve overall survival in optimally debulked advanced ovarian cancer patients?
135 mg/m2 Paclitaxel IV, over 24hrs
cisplatin 75mg/m2 IV on day 2
q3wks x6 cycles
135 mg/m2 paclitaxel IV, over 24hrs
cisplatin 100 mg/m2 IP day 2
60 mg/m2 Paclitaxel IP day 8
q3wks x6 cycles
OS
Stage III epithelial ovarian carcinoma
Residual disease ≤1cm
IP/IV vs IV:
median f/u: 48.2 mos
median PFS: 23.8 vs. 18 mos (SS)
median OS: 65.6 vs 49.7 m (SS)
Completed 6 cycles: 42% vs 83% (SS)
G3/4 GI Toxicity: 46% vs 24% (SS)
G3/4 Neutropenia: 76% vs 64% (SS)
G3/4 Neuropathy: 19% vs 9% (SS)
G3/4Fatigue: 18% vs 4% (SS)
IP/IV chemotherapy resulted in significantly improved PFS and OS in optimally debulked patients with advanced ovarian cancer